Article Commentary: Who's in Favor of Translational Cell Therapy for Stroke: STEPS Forward Please?

Cell Transplantation

Commentary

Douglas Kondziolka¹  Michael Chopp²  Mei Lu²  Yi Li²  David C. Hess³  Cesario V. Borlongan⁴  Tonya M. Bliss⁵  Gary K. Steinberg⁵ 

[1] Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA;Department of Neurology, Henry Ford Hospital, Detroit, MI, USA;Department of Neurology, Medical College of Georgia, Augusta, GA, USA;Department of Neurology, Medical College of Georgia, Augusta, GA, USA;Department of Neurosurgery, University of South Florida, Tampa, FL, USA;Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA;

关键词: Stem cell transplantation;    Tissue regeneration;    Cellular therapy;    Clinical translation;   

DOI  :  10.3727/096368909X470883

 received in 2008-12-18, accepted in 2009-02-24,  发布年份 2009

来源: Sage Journals

【 摘 要 】

A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.

【 授权许可】

Unknown   
© 2009 Cognizant Comm. Corp.